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and Stephen J. Lippard§
From the Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139

The high mobility group (HMG) domain is a DNAbinding motif found in the non-histone chromosomal
proteins, HMG1 and HMG2, and some transcription factors. Experimental evidence has demonstrated that
HMG-domain proteins can play a role in sensitizing cells
to the anticancer drug cisplatin. Fluorescence resonance energy transfer (FRET) experiments were performed in the present study to investigate structural
changes that accompany complex formation between
the HMG domain B of HMG1 and a cisplatin-modified,
20-base pair double-stranded DNA probe containing fluorescein and rhodamine tethered at its two ends. The
binding affinity of HMG1 domain B for the cisplatinmodified DNA probe was investigated in fluorescence
titration experiments, and a value of 60 6 30 nM was
determined for the dissociation constant. Single photon
counting methods were employed to measure the fluorescence lifetime of the fluorescein donor in the presence and absence of HMG1 domain B. These FRET experiments revealed a distance change that was used to
estimate a bend angle of 80 –95° for the cisplatin-modified DNA upon protein binding. Stopped-flow fluorescence spectroscopic experiments afforded kinetic parameters for HMG1 domain B binding to the cisplatinmodified DNA probe, with kon 5 1.1 6 0.1 3 109 M21 s21
and koff 5 30 6 4 s21.

The long term survival for testicular cancer patients treated
with cis-diamminedichloroplatinum(II) (cisplatin),1 exceeds
90% (1). If the detailed mechanism of action of this anticancer
drug could be determined, analogs might be designed to
broaden its organotropic profile. It is generally accepted that
the biological target of cisplatin is DNA, the major adducts
formed being 1,2-intrastrand d(GpG) and d(ApG) cross-links
involving platinum binding to the N-7 atoms of the purine
bases (2). Formation of these adducts unwinds the DNA and
bends it toward the major groove (3–7), blocking transcription
and replication. The ability to distort DNA structure cannot
fully explain the anticancer activity because the geometric
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1
Theabbreviationsusedare:cisplatin,cis-diamminedichloroplatinum(II); HMG, high mobility group; bp, base pair(s); FRET, fluorescence
resonance energy transfer; Nd:YAG, neodymium:yttrium-aluminumgarnet; MCP-PMT, microchannel plate photomultiplier tube; HPLC,
high performance liquid chromatography; W, watt(s).

isomer of cisplatin, trans-diamminedichloroplatinum(II),
which also forms DNA adducts that modify the structure and
block transcription and replication, is clinically ineffective. Efforts have therefore focused on identifying other cellular constituents that might interact specifically with cisplatin-DNA
adducts to effect the antineoplastic response.
By screening human and yeast cDNA expression libraries,
genes were discovered for proteins that bind specifically to
cisplatin-modified DNA (8, 9). These proteins, human structure-specific recognition protein (hSSRP1) and intrastrand
cross-link recognition protein (Ixr), both contain 80-amino acid
peptides homologous to the DNA-binding domains of the chromosomal protein HMG1. HMG1 is the prototypical member of
a family of proteins that contain such DNA-binding motifs.
Most HMG-domain proteins bind specifically to the major cisplatin-DNA adducts, increasing the bend angle by up to 60°, as
determined through gel mobility shift assays (10 –13). HMG
domain proteins shield cisplatin-DNA adducts from excision
repair both in yeast cells and in human cell extracts, suggesting that they may play a role in the mechanism of action of
cisplatin (11, 14, 15). SSRP1 has recently been associated with
a factor involved in transcription elongation,2 offering further
clues for how these proteins might be involved in the antitumor
activity.
In the present work, fluorescence resonance energy transfer
(FRET) was developed as a probe for the further characterization of HMG-domain protein binding to cisplatin-modified
DNA. This technique is based on the coupling of transition
dipoles between two fluorescent dyes, a donor and an acceptor,
attached to a macromolecule. The efficiency of the energy
transfer between donor and acceptor depends on the distance
between them (16). As the distance decreases, the efficiency of
the energy transfer should increase. The FRET technique responds to small changes in distance in the range of 10 –75 Å
(16) and can reveal increased bending caused by an HMGdomain protein binding to cisplatin-modified DNA. In addition,
FRET has the potential to facilitate kinetic studies of the
interaction.
FRET has been used extensively to examine different types
of nucleic acid structures (17–23). It has also been applied to
study the structure of protein-DNA complexes (24 –27). Recently, FRET techniques were used to investigate bending
within a 30-bp oligonucleotide that accompanies the binding of
the HMG-domain protein Chironomus HMG1 (26). The FRET
distance measurements determined for the Chironomus
HMG1-DNA complex enabled a bend angle of 150° to be estimated for the DNA in that complex. Experiments undertaken
here similarly examine the bend angle induced when an HMG
domain protein binds to cisplatin-modified DNA. A 20-bp oli-
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FIG. 1. Description of the oligonucleotides used in FRET studies. Fl is
fluorescein, and Rh is rhodamine. The
structures of the succinimidyl ester forms
of the dyes used to label the oligonucleotides are depicted. Fl-ds is the fluorescein-labeled probe. Pt/Fl-ds is the platinated fluorescein-labeled probe. Rh/Fl-ds
is the rhodamine- and fluorescein-labeled
probe. Pt/Rh/Fl-ds is the platinated rhodamine- and fluorescein-labeled probe.
The 1,2-intrastrand d(GpG) cisplatin adduct is denoted by asterisks.

gonucleotide probe modified with fluorescein as the donor and
rhodamine as the acceptor was synthesized having a single
cisplatin cross-link. Studies of the binding of HMG1 domain B
to this FRET probe revealed the increased bending that accompanied protein-DNA complex formation, demonstrating the viability of this approach.
In addition to examining the structural change that accompanies HMG1 domain B binding, FRET was employed to monitor the kinetics of the interaction by using stopped-flow techniques. Stopped-flow fluorescence spectroscopic experiments
have afforded information about the rates of binding for several
other protein-DNA complexes (25, 28 –31). In these studies,
changes in either the intrinsic protein fluorescence or in a DNA
probe containing a fluorescent label, resulting from proteinDNA complex formation, were monitored over time. The kinetics of yeast TATA-binding protein interacting with promoter
DNA were revealed by FRET (25). As in the present work,
these experiments used a fluorescein- and rhodamine-labeled
DNA probe to follow protein-DNA complex formation. Here we
provide the first quantitative information about the rates at
which an HMG-domain protein binds to and dissociates from
cisplatin-modified DNA.
EXPERIMENTAL PROCEDURES

Materials and Methods—Distilled, deionized water from a Milli-Q
system (Millipore) was used to prepare aqueous solutions. Atomic absorption spectrometry was performed on a Varian AA1475 instrument
with a GTA95 graphite furnace. High performance liquid chromatography (HPLC) was carried out by using a Waters 600E system controller
equipped with either a Waters 484 or 486 detector.
Expression and Purification of Recombinant Rat HMG1 Domain
B—This protein was obtained as described (13) with the following
modifications. Escherichia coli cells were grown in LB media and lysed
by sonication. After passing through the S-Sepharose column, the protein was purified by using an FPLC Superdex 75 size exclusion column
(Amersham Pharmacia Biotech). The eluent for the Superdex 75 column was phosphate-buffered saline (1 mM KH2PO4, 10 mM Na2HPO4,
0.137 M NaCl, and 2.7 mM KCl, pH 7.4) with a flow rate of 0.5 ml/min.
Synthesis and Purification of Rhodamine- and Fluorescein-labeled
Oligonucleotide Probes—The 20-bp oligonucleotide probes with N-TFA
C6 Amino Modifier (Cruachem) attached to the 59 end were synthesized
on a Cruachem PS250 DNA synthesizer by using standard cyanoethylphosphoramidite chemistry. The crude deprotected oligonucleotides
were purified by size exclusion chromatography on a G-25 Sephadex
(Amersham Pharmacia Biotech) column using distilled, deionized water
as the eluent. The top strand was modified with 5- and 6-carboxytetramethylrhodamine, succinimidyl ester (Molecular Probes), and the bottom strand was modified with 5- and 6-carboxyfluorescein, succinimidyl
ester (Molecular Probes). The composition of the reaction mixture was

200 mM oligonucleotide, 5 mM rhodamine or fluorescein, respectively,
and 0.1 M sodium carbonate buffer, pH 9.0. The reactions were stirred
at room temperature for approximately 72 h. When the reactions
were complete, excess unreacted dye was removed by using Centriplus
3 concentrators (Amicon) followed by dialysis (Mr cut-off 1000,
Spectra/Por).
The FRET probes were purified by reverse phase HPLC on a Vydac
C4 preparatory column (22 3 250 mm, 10-mm particle size) using a flow
rate of 10 ml/min. Buffer A was 0.1 M NH4OAc, and Buffer B was 0.5 M
NH4OAc in 50% CH3CN. The gradient used was 90% Buffer A to 60%
Buffer A over 30 min, followed by 60% Buffer A to 50% Buffer A over 10
min. Because the rhodamine and fluorescein dyes employed in the
syntheses were a mixture of the 5- and 6-succinimidyl ester isomers,
two FRET probes were observed for each synthesis in the HPLC trace.
The 5-isomer was the dominant product, eluting with a greater retention time for oligonucleotides labeled with both rhodamine (;25 min)
and fluorescein (;20 min), and therefore was used in the FRET experiments. Electrospray mass spectrometry was used to characterize the
rhodamine-labeled top strand and fluorescein-labeled bottom strand.
The molecular mass determined for the rhodamine-labeled top strand
with one sodium ion was 6543.45 Da (calculated mass, 6543.03 Da), and
the molecular mass determined for the fluorescein-labeled bottom
strand with one sodium ion was 6819.45 Da (calculated mass, 6819.03
Da).
Reaction of Cisplatin with the Rhodamine Probe—The purified rhodamine probe was lyophilized, dissolved in distilled, deionized water,
and passed through a Dowex 50 3 8 –200 (Aldrich) ion exchange column
to exchange the ammonium ions for sodium ions. An activated cisplatin
solution was made by reaction with 1.97 mol eq of AgNO3 (Aldrich) in
distilled, deionized water on a shaker at room temperature overnight in
the dark followed by centrifugation to remove the AgCl precipitate. The
rhodamine-modified probe was platinated by addition of the activated
cisplatin solution (2 eq) to a 100 mM solution of the oligonucleotide. The
reaction mixture was incubated at 37 °C for ;3 h. The product was
purified by HPLC, using a Dionex Nucleopac PA-100 (9 3 250 mm)
preparatory column at a flow rate of 4 ml/min. It was then eluted with
a gradient of 75% Buffer A (0.025 M NH4OAc in 10% CH3CN) to 50%
Buffer A/Buffer B (0.025 M NH4OAc, 1 M NaCl in 10% CH3CN) over 30
min. The collected peak was dialyzed (Mr cut-off 1000, Spectra/Por)
against distilled, deionized water for 48 h. Platinum atomic absorption
spectroscopy revealed there to be one platinum atom per oligonucleotide
strand.
Synthesis and Purification of Unlabeled Oligonucleotide Probes—A
portion of the 20-bp top strand with the C6 amino modifier described
above was purified by HPLC on a Dionex Nucleopac PA-100 (9 3 250
mm) preparatory column. The flow rate was 4 ml/min, and the gradient
and buffers were as described above for the rhodamine probe. The
collected peak was dialyzed as above. This top strand was used to make
the unplatinated, fluorescein-labeled control duplex probe (Fl-ds). The
unlabeled cisplatin-modified top strand was made as described previously (32) and used to make the platinated, fluorescein-labeled control
duplex probe (Pt/Fl-ds).
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Purification of the Fluorescent Duplex Probes—Fig. 1 shows a schematic drawing of the four different oligonucleotide duplex probes and
their abbreviations. The fluorescein-labeled bottom strand was combined with unlabeled top strand, with unlabeled, cisplatin-modified top
strand, with rhodamine-labeled top strand, or rhodamine-labeled, cisplatin-modified top strand to make the four different FRET probes.
Equimolar amounts of the top and bottom strands were combined in a
solution containing 10 mM Tris, pH 7.0, 50 mM NaCl, and 10 mM MgCl2.
The solution was heated to 90 °C and slowly cooled to 4 °C over several
hours. The duplex DNA was purified by ion exchange HPLC to remove
excess single-stranded material. A Dionex Nucleopac PA-100 (9 3 250
mm) preparatory column was used at a flow rate of 4 ml/min and a
gradient of 70% Buffer A to 45% Buffer A over 30 min, followed by 45%
Buffer A to 0% Buffer A over the next 10 min. Under these conditions,
the duplexes eluted at ;35 min. The collected samples were dialyzed
against distilled, deionized water for 48 h as above, and the resulting
solutions were lyophilized to dryness. The duplex samples were redissolved in 10 mM Tris, pH 7.0, 50 mM NaCl, and 10 mM MgCl2. The
solutions were heated to 90 °C and slowly cooled to 4 °C over several
hours. A Dionex Nucleopac PA-100 (4 3 250 mm) column was used to
check the purity of the final duplex materials by analytical ion exchange
HPLC.
Fluorescence Titration Experiments with HMG1 Domain B—These
experiments were performed with a Hitachi F-3010 spectrofluorimeter
at 25 °C. Emission spectra were recorded of both the unmodified and
cisplatin-modified duplex probes labeled with both fluorescein and rhodamine in 10 mM HEPES, pH 7.0, and 200 mM NaCl solution in the
presence of increasing concentrations of HMG1 domain B. The excitation wavelengths used were 480 and 550 nm, and fluorescence emission
spectra were observed at 490 – 610 and 560 – 610 nm, respectively.
Emission spectra obtained from exciting at 550 nm (rhodamine fluorescence only) were used to correct the data for dilution and photobleaching effects. The corrected emission spectral data at 520 nm were used to
determine the dissociation constant, Kd.
Kd values were determined by plotting the change in fluorescence
intensity at 520 nm, DF, against the total protein concentration, [Pt].
The data were fit to the expression described in Equation 1, where [Dt]
is the total oligonucleotide concentration and c is a constant that relates
fluorescence intensity (I) to concentration. The average value of c was
determined to be 1.8 6 0.5 3 1029 M I21. This equation is derived
directly from the equilibrium mass action expression with no assumptions. The value of [Dt] was set to be the concentration of DNA used in
each titration experiment.
DF 5

~Kd 1 @Pt# 1 @Dt#! 2

Î~Kd 1 @Pt# 1 @Dt#!2 2 4@Dt#@Pt#
2c

converter (Canberra 2145) was utilized in “reverse” mode, such that
pulses from the MCP-PMT provided the “start” pulse, and a timedelayed photodiode (Antel Optronics, ARX-SP, 210-ps rise time) pulse
provided the “stop” pulse. The ratio of the photon detection rate to the
laser repetition rate was at all times less than 1%, and usually below
0.001. The output of the time-to-amplitude converter was temporarily
stored in a multichannel analyzer (Nucleus, Inc., Oak Ridge, TN) and
processed on a personal computer. Typical signal integration time was
5 min for one decay measurement.
The fluorescence lifetime of the fluorescein dye was measured for 16
different samples by using the apparatus described above. The concentration of all DNA probes was 40 nM duplex in 10 mM HEPES, pH 7.0,
and 200 mM NaCl. HMG1 domain B protein was added to the duplex
DNA solutions, and fluorescence lifetime data were taken at 0, 1, 10,
and 20 eq of added protein.
Fluorescence Lifetime Data Analysis—The fluorescein lifetime data
were analyzed by using standard least-squares methods. The decays
were assumed to conform to Equation 2 (33), in which D(t) is the “true”
decay function, R(t) is the instrument response function, determined
experimentally to have a full width at half-maximum of 270 ps by
scattering ps laser pulses at the MCP-PMT, and C and to are constants.
I~t! 5 R~t 1 to! ^ D~t! 1 CR~t 1 to!

The CR(t 1 to) term provides a correction for laser scatter, which was
very difficult to eliminate completely, but always accounted for less
than 1% of the detected photons. This correction assumes that the
contribution of the scatter to the decay curve is identical to the instrument response function, that is, that all of the scatter arrives at the
detector at t 5 0. The constant to serves simply to set the zero of time.
Both single and double exponential fits were performed (see below). For
a single exponential fit, A exp(2t/t), the total number of fitted parameters would be four: A, amplitude of decay; t, lifetime; C, amplitude of
scattered light; and to, zero time. The least-squares algorithm employed
was a modified version of the Levenberg-Marquardt routine provided by
Numerical Recipes (34).
The fluorescence lifetimes obtained from the fitting of the decay
curves were used to calculate the FRET efficiencies and distances. The
efficiency of energy transfer between donor and acceptor can be calculated by using Equation 3, where E is the efficiency of the energy
transfer, tDA is the fluorescence lifetime of the donor in the presence of
acceptor, and tD is the fluorescence lifetime of the donor in the absence
of acceptor (16).
E 5 1 2 tDA/tD

(Eq. 1)

Fluorescence Lifetime FRET Experiments—Time-correlated, single
photon counting methods were employed to determine the fluorescence
lifetime of the fluorescein in the oligonucleotide duplex probes. Light
excitation was accomplished with a synchronously pumped, modelocked, cavity-dumped picosecond dye laser system. The PUMP laser
was a mode-locked Coherent Antares 76-s Nd:YAG (neodymium:yttrium-aluminum-garnet) system, which produced 22 W of 1.06-mm radiation in approximately 80-ps pulses at a repetition rate of 76.0 MHz.
External frequency doubling and tripling units (CSK Optronics) were
utilized to generate 1.6 W of 355-nm light, which pumped the laser dye
coumarin 2 in the home-built system consisting of an extended-cavity
Coherent 590 dye laser equipped with a Coherent 7220 cavity dumper.
Approximately 15 mW of 450 nm light was generated at a repetition
rate of 7.6 MHz, with pulse width of ;5 ps.
The sample was contained in a 1-ml fluorescence cuvette (10 3 10
mm), surrounded by an ice bath to ensure constant temperature, and
irradiated within a light-tight box. The fluorescence was detected at
right angles to the laser beam; no collection optics were employed, but
the size of the active area on the microchannel plate photomultiplier
tube (MCP-PMT; 2.0 inches in diameter) and its proximity to the
sample (6 inches) ensured nearly f/3 collection efficiency. A combination
of colored glass filters (Schott) was employed to act as a notch filter and
block from the detector both scattered laser light and emission from the
rhodamine on the fluorescent duplexes. This filter combination passed
only a narrow band of wavelengths around 500 nm (30 nm, full width at
half-maximum).
Fluorescence was detected with a two-stage MCP-PMT (Hamamatsu
R1564u) having a rise time of 70 ps. The MCP-PMT output was directed
through two gain 10, 2.0-GHz preamplifiers (Sonoma Instrument) and
then into a constant fraction discriminator (Tennelec TC454). To take
advantage of the high repetition rate of the laser, the time-to-amplitude

(Eq. 2)

(Eq. 3)

The distance between donor and acceptor, R, can be calculated from the
FRET efficiency, E, according to Equation 4, where Ro is a characteristic
distance related to the properties of the donor and acceptor at which
50% of the energy is transferred (16).
R6 5 Ro6~1 2 E!/E

(Eq. 4)

An Ro value of 45 Å determined for fluorescein and rhodamine (20) was
used to calculate R.
Modeling the HMG1 Domain B Complex with Cisplatin-modified
DNA—Fig. 2 displays the geometric model used to evaluate a bend
angle for the HMG1 domain B complex with cisplatin-modified DNA.
This model is based on one (20, 22) where the 20-bp oligonucleotide is
represented as a cylinder with the donor and acceptor dyes extending
from the ends. Vectors describing the positions of the dyes are determined as the cylinder bends and used to calculate the distance between
the dyes. The hinge point of the bend is chosen as the midpoint of the
central axis of the cylinder and is designated as the origin in (x, y, z)
space.
The molecular modeling program QUANTA (Molecular Simulations,
Inc.) was used to determine the initial positions of the donor and
acceptor dyes. The first aspect examined in the model was the distance
of the dyes relative to the center of the cylinder. Models of the two
fluorescent dyes with their six-carbon linker chains were constructed
and minimized by using the CHARMM routine contained in QUANTA.
The measured distance from the center of the fluorophores to the end of
the linker chain was ;1.45 nm for both dyes. If the radius of the DNA
is assumed to be 1.0 nm, then the perpendicular distance of the dyes
from the center of the cylinder will be 2.45 nm. The dyes may bend in
toward or away from the center of the cylinder, as shown in Fig. 2. By
keeping the 1.0-nm cylinder radius constant and allowing the 1.45-nm
dye vector to bend, one can determine the components of the 1.45-nm
vector that are perpendicular and parallel to the central cylinder axis.
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FIG. 2. Geometric model used to calculate bend angle (u) for fluorescence
lifetime data. The cylinder represents
the 20-bp oligonucleotide. The dyes, labeled Rh and Fl for rhodamine and fluorescein, respectively, are allowed to bend
toward and away from the normal to the
cylinder axis at some angle, a. The model
requires the determination of both the
parallel (i) and perpendicular (') components of the dye vectors. The definition of
the (x, y, z) axes used in the model is
shown here.

The second crucial aspect of this model is the position of the fluorescent dyes relative to the bend in the DNA. In order to determine these
positions, a B-form DNA model of the 20-bp oligonucleotide was constructed in QUANTA with a rhodamine dye docked onto the 59 end of
the top strand and a fluorescein dye docked onto the 59 end of the
bottom strand. A cisplatin fragment analog, cis-{Pt(NH3)(NH2(CH2)nCH3)}21, was docked to the N-7 positions of the guanines in
the top strand to mark the location of the 1,2-intrastrand d(GpG)
cross-link and the corresponding DNA bend. Fig. 3 shows this model,
which displays the positions of the fluorescent dyes relative to the
cisplatin directed bend when projected down the helix axis. This view
represents a slice of the cylinder in an (x, z) plane with the hinge point,
(0, 0), lying in the center of the helix. The cisplatin adduct is defined to
lie on the x axis. Measuring the angle between the vectors describing
the position of the dyes and the x axis allows the components of these
vectors along the x and z axes to be determined. In this case, the angle
between the rhodamine vector and the x axis is 70°, and the angle
between the rhodamine and fluorescein vectors is 200°. The latter value
is in relatively good agreement with the value of 227° used by others
(20).
In order to determine the vectors describing the positions of the dyes,
both aspects of the model described above were combined. First, the
perpendicular components of the 1.45-nm dye vectors were determined
as they bend in toward and away from the cylinder. The magnitude of
these components was used along with the angles determined in Fig. 3
to calculate the components of the dye vectors along the x and z axes.
The component of the vector along the y axis is the sum of the parallel
component of the 1.45-nm dye vector combined with the length of half
the cylinder. In this case, since the hinge point is located in the center
of the helix, its distance to the top of the cylinder is 3.4 nm (0.34 nm/bp
for 10 bp). Once the vectors were determined for a series of rhodamine
and fluorescein angles, the distance between the two dyes was
calculated.
Only certain rhodamine and fluorescein angle pairs will yield the
6.4-nm distance (see “Results and Discussion”) determined for the unplatinated, linear duplex in these FRET experiments. Pairs of fluorescein and rhodamine angles compatible with the 6.4-nm distance are
revealed by the plot shown in Fig. 4. Although all of these allowed angle
pairs yield a 6.4-nm distance for the unbent cylinder, some of the
positions are preferred by the dyes. Fluorescence anisotropy experiments have indicated that fluorescein tends to have a low anisotropy
value, indicative of high rotational freedom, whereas rhodamine tends
to have a high anisotropy value, suggestive of an interaction between its
dimethylamino groups and the phosphate backbone of the DNA (17, 20,
35). Thus, those allowed angle pairs where rhodamine has a negative
angle and is bent toward the DNA may be preferred over those where
the dye has a positive angle and is bent away from the DNA. It is
important to keep in mind that these allowed angles are only average
positional preferences. The dyes are assumed to rotate freely in the
FRET equations used above to calculate distances. In the bend angle
calculations described below, the preferred allowed angle pairs were
examined together with positions that may be less favored.
The bending of the cylinders was performed in (x, y) space as depicted
in Fig. 2 for the allowed rhodamine and fluorescein angle pairs calcu-

FIG. 3. A view down the helix axis of a 20-bp B-form DNA helix.
Rhodamine is attached to the 59-end of the top strand, and fluorescein
is attached to the 59-end of the bottom strand. A cisplatin analog is
docked onto the guanines of the top strand to indicate the position of the
DNA bend. The angles observed between the dyes and the x axis in this
figure are used in the geometric model to help determine the vectors
describing the positions of the dyes.
lated above. As the cylinder bends, the position of the rhodamine dye,
and hence the vector which describes its position, was kept constant to
simplify the model. The bottom half of the cylinder and the fluorescein
dye moves in (x, y) space. By allowing the cylinder to bend only in an (x,
y) plane, the position of the fluorescein dye relative to the z axis remains
constant. The x and y components of the fluorescein vector change as
the cylinder bends (Fig. 5). New fluorescein vectors for each bend angle
were calculated from the altered x and y components. These new vectors
were used with the rhodamine vector to determine the distance between
the dyes. The bend angle that predicts the measured 5.5-nm distance
(see below) between the dyes was thus estimated for the HMG1 domain
B protein-DNA complex.
The above model does not take into account DNA unwinding, which
might accompany platinum or protein binding. In order to do so, the
initial positions of the dyes described in Fig. 3 need to be altered. The
average helical twists found in the x-ray crystal structure and NMR
solution structures for a 1,2-intrastrand d(GpG) cisplatin adduct were
used to alter the initial positions of the dyes from Fig. 3 (6, 7, 36). The
6.6-nm distance measured for the platinated duplex without protein
was used to calculate the allowed fluorophore angle positions. Those
angle pairs that have the dyes separated by 6.6 nm when the DNA
bends by the angles observed in the x-ray and NMR studies were used
in the geometric model. With these new initial parameters, the dis-
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FIG. 4. A plot of the allowed fluorescein and rhodamine angle
pairs for the geometric model using the B-form DNA parameters
and the 6.4-nm distance measured for the unmodified FRET
probe. There are many different allowed angle pairs. Those with rhodamine having a negative angle and fluorescein having a positive angle
are preferred based on anisotropy studies and are denoted by the
shaded area. These allowed angles are representative of those average
positions in space where a 6.4-nm distance will be found.

FIG. 5. A schematic drawing of how the fluorescein dye vector
is determined as the cylinder bends. Since the cylinder bends in (x,
y) space, the component of the fluorescein vector along the z axis will not
change with u. The components of the vector along the x and y axes
change as follows: (x92 1 y92) cos((90 1 b) 2 u) (for x axis) and 2(x92 1
y92) sin((90 1 b) 2 u) (for y axis). The angle, b, is equal to the tan21
(x9/y9).
tances between the dyes as the cylinder bends were calculated as
described above.
Stopped-flow Kinetic Studies with HMG1 Domain B—These experiments were performed with a Hi-Tech SF-61 DX2 double mixing
stopped-flow apparatus at 4 °C. HMG1 domain B was combined with 25
nM unmodified or cisplatin-modified duplex probes labeled with both
fluorescein and rhodamine in 10 mM HEPES, pH 7, 200 mM NaCl.
Pseudo-first order kinetic conditions were maintained by using at least
a 5-fold excess of protein in all experiments. The excitation wavelength
was 480 nm. A GG495 glass cut-off filter and a Wratten gel filter no. 58
(Eastman Kodak) were placed over the exit to the photomultiplier tube.
This filter pair served to block rhodamine fluorescence and transmit the
FRET-induced fluorescein fluorescence change.
Concentration-dependent studies were performed with the cisplatinmodified probe and HMG1 domain B to determine the rate constants for
the binding and dissociation of this protein-DNA complex. In these
experiments, the protein concentration was varied from 0.125 to 1 mM.
Multiple shots were taken at each protein concentration. The observed
rate constants for the protein concentrations were determined by fitting
individual traces with the KinetAssyst software package (Hi-Tech) and
averaging the results. The observed rate constant, kobs, was plotted
against the total protein concentration, [Pt]. The resulting linear plot is
described by Equation 5, where kon is the second-order rate constant for
protein binding and koff is the first-order rate constant for the dissoci-

FIG. 6. Emission spectra from fluorescence titration experiments. A, Pt/Rh/Fl-ds with increasing HMG1 domain B; B, Rh/Fl-ds
with increasing HMG1 domain B; C, Pt/Rh/Fl-ds titrated with distilled,
deionized water. The inset to A shows an enlargement of the spectral
region from 565 to 600 nm to highlight the increase in rhodamine
fluorescence.
ation of the protein-DNA complex.
kobs 5 kon@Pt# 1 koff

(Eq. 5)

In these experiments, the least-squares fit of each point was weighted
by the number of shots averaged to determine the kobs value. The rate
constants, determined in Equation 5, were used to calculate a dissociation constant, Kd, for the protein-DNA complex according to Equation
6.
Kd 5 koff/kon

(Eq. 6)

RESULTS AND DISCUSSION

Determination of Kd from Steady-state Fluorescence Titration
Experiments—Fig. 6 shows emission spectra from three different fluorescence titration experiments in which the fluorescein
dye was excited at 480 nm and emission spectra were recorded
from 490 to 610 nm. The fluorescein emission maximum occurs
at 520 nm, and the rhodamine emission maximum at 580 nm.
Panel A of Fig. 6 presents the results of titrating Pt/Rh/Fl-ds
with increasing amounts of HMG1 domain B. The inset enlarges the spectral region from 565 to 600 nm. Panel B displays
the unplatinated Rh/Fl-ds sample with increasing amounts of
HMG1 domain B, and panel C shows the platinated Pt/Rh/Fl-ds
probe titrated with distilled, deionized water instead of protein.
The results clearly demonstrate that significant spectral

FRET and HMG1 Domain B Binding to Cisplatin-modified DNA

12351

FIG. 7. Determination of Kd from titration data. The data shown
are for a single titration experiment fit to Equation 1. Several experiments were carried out, and the results averaged to determine the final
dissociation constant value.

changes occur only when the platinated probe is titrated with
protein.
From the decrease in the fluorescence intensity at 520 nm for
the fluorescein donor and the increase in the fluorescence emission of the rhodamine acceptor dye at 580 nm with increasing
protein concentration (inset), it is clear that FRET occurs. We
ascribe this result to protein-induced bending of the platinated
DNA. The spectral observed changes were used to determine
the dissociation constant of this protein-DNA complex. The
change in fluorescence intensity at 520 nm (DF) is directly
related to the concentration of the protein-DNA complex, assumed to have a 1:1 stoichiometry. Plots of DF versus [Pt] (Fig.
7) were fit by least squares to Equation 1, affording an average
dissociation constant of 60 6 30 nM.
Recently, a series of cisplatin-modified 15-bp oligonucleotides were reported to have a range of dissociation constants for
the HMG1 domain B complex of 50 –1300 nM (37), as determined by gel mobility shift assays. The value of 60 6 30 nM
determined here falls within this range, but is ;8 times
smaller than the one previously determined for the identical
20-bp oligonucleotide by gel mobility shift assay (13). This
discrepancy is ascribed to differences in the experimental conditions, the present experiments being performed at a different
temperature and with different buffer conditions than in the
gel mobility shift assay.
Duplex End-to-end Distance from Fluorescein Fluorescence
Lifetime Measurements—Fluorescence emission decay curves
were obtained and the data were analyzed as described above.
An example of a fitted fluorescence emission decay curve is
presented in the upper panel of Fig. 8. The bottom panel of this
figure depicts the weighted residuals of the fit, (Iobs 2 Icalc)/si,
where si is the standard deviation associated with Iobs, si 5
(Iobs)0.5. Most of the weighted residuals lie within two standard
deviations. The fluorescence lifetime values obtained from fitting the decay curves are presented in Table I.
The data in Table I show that, for the fluorescein-labeled
(Fl-ds), platinated fluorescein-labeled (Pt/Fl-ds), and rhodamine- and fluorescein-labeled (Rh/Fl-ds) duplex oligonucleotides, the fluorescein fluorescence lifetime either remains the
same or increases slightly with increasing concentrations of
HMG1 domain B. The data for the platinated oligonucleotide
with rhodamine and fluorescein (Pt/Rh/Fl-ds) clearly display a
different trend. The lifetime of fluorescein in this probe in the
absence of added protein is slightly increased from that of the
Rh/Fl-ds duplex, presumably due to DNA unwinding and bending upon platination. When increasing concentrations of HMG1
domain B were added, there was a significant decrease in
fluorescence lifetime of the fluorescein label. This difference in
lifetimes is apparent in the decay curves plotted in Fig. 9, the

FIG. 8. Example of a fitted fluorescence emission decay curve.
Data were fitted as described under “Experimental Procedures.” The
upper panel shows the fitted decay curve, and the lower panel depicts
the weighted residuals of the fit.
TABLE I
Fluorescein lifetime values obtained from single exponential fits of the
single photon counting dataa
Sampleb

Fluorescein lifetime
ns

Fl-ds
Fl-ds 1 1 eq HMGdomB
Fl-ds 1 10 eq HMGdomB
Fl-ds 1 20 eq HMGdomB

4.03 (1)
4.02 (1)
4.10 (1)
4.14 (1)

Pt/Fl-ds
Pt/Fl-ds 1 1 eq HMGdomB
Pt/Fl-ds 1 10 eq HMGdomB
Pt/Fl-ds 1 20 eq HMGdomB

4.03 (1)
3.99 (1)
4.04 (2)
4.12 (1)

Rh/Fl-ds
Rh/Fl-ds 1 1 eq HMGdomB
Rh/Fl-ds 1 10 eq HMGdomB
Rh/Fl-ds 1 20 eq HMGdomB

3.59 (1)
3.64 (2)
3.62 (1)
3.62 (1)

Pt/Rh/Fl-ds
Pt/Rh/Fl-ds 1 1 eq HMGdomB
Pt/Rh/Fl-ds 1 10 eq HMGdomB
Pt/Rh/Fl-ds 1 20 eq HMGdomB

3.65 (1)
3.63 (1)
3.24 (1)
3.18 (1)

a
Numbers in parentheses are standard deviations in the last significant digit. Oligonucleotide probe concentrations were 40 nM in all
samples.
b
Fl-ds is the fluorescein-only-labeled probe. Pt/Fl-ds is the platinated, fluorescein-only-labeled probe. Rh/Fl-ds is the probe labeled with
both fluorescein and rhodamine. Pt/Rh/Fl-ds is the platinated probe
labeled with both fluorescein and rhodamine.

log format of which emphasizes the effect. In this figure, the
Pt/Fl-ds and Pt/Rh/Fl-ds probes with no protein are compared
with the Pt/Rh/Fl-ds probe with 20 eq of added HMG1 domain
B. The longest fluorescence lifetime is for fluorescein in the
Pt/Fl-ds sample. The lifetime shortens when the acceptor dye is
present, and with 20 eq of HMG1 domain B the Pt/Rh/Fl-ds
probe exhibits the shortest fluorescence lifetime. The changes
are consistent with FRET induced by protein binding and bending the platinated DNA.
The fluorescence lifetime values were used to calculate
FRET efficiency (E) and the distance (R) between the dyes in
these different samples. Table II shows the results computed
by Equations 3 and 4 for the Rh/Fl-ds and Pt/Rh/Fl-ds probes.
As expected from the lifetime studies, the Rh/Fl-ds samples
exhibit only a small increase in FRET efficiency with increas-
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TABLE III
Double exponential fits to data for Pt/Rh/Fl-ds samples with excess
HMG1 domain B
Numbers in parentheses are standard deviations in the last significant digit.

FIG. 9. Normalized fluorescence lifetime decay curves for
some selected samples. Curves for Pt/Fl-ds, Pt/Rh/Fl-ds, and Pt/Rh/
Fl-ds with 20 eq HMG1 domain B are depicted. Plots are shown in log
scale for clarity.
TABLE II
FRET efficiency and distance data
Numbers in parentheses are standard deviations in the last significant digit.
Samplea

FRET efficiency

Distance (R)

E

nm

Rh/Fl-ds
Rh/Fl-ds 1 1 eq HMGdomB
Rh/Fl-ds 1 10 eq HMGdomB
Rh/Fl-ds 1 20 eq HMGdomB

0.11 (1)
0.09 (1)
0.12 (1)
0.12 (1)

6.4 (1)
6.6 (1)
6.3 (1)
6.3 (1)

Pt/Rh/Fl-ds
Pt/Rh/Fl-ds 1 1 eq HMGdomB
Pt/Rh/Fl-ds 1 10 eq HMGdomB
Pt/Rh/Fl-ds 1 20 eq HMGdomB

0.09 (1)
0.09 (1)
0.20 (2)
0.23 (2)

6.6 (1)
6.6 (1)
5.7 (1)
5.5 (1)

a
Rh/Fl-ds is the probe labeled with both fluorescein and rhodamine.
Pt/Rh/Fl-ds is the platinated probe labeled with both fluorescein and
rhodamine.

ing protein concentrations, corresponding to a decrease in distance of only ;0.1 nm, from 6.4 to 6.3 nm. The Pt/Rh/Fl-ds
samples, however, show a dramatic increase in FRET efficiency, from 0.09 to 0.23 with increasing protein concentrations. This result reflects a change in distance between donor
and acceptor of 21.1 nm, from 6.6 to 5.5 nm. The 17% decrease
may be attributed to protein binding and concomitant DNA
bending.
Most of the fluorescence decay curves were adequately fit to
a single-exponential function. The Pt/Rh/Fl-ds samples containing excess HMG1 domain B deviated the most from single
exponential behavior. Double-exponential fits were therefore
investigated, the results of which are reported in Table III. The
double-exponential fits at the higher concentrations of protein
afford fluorescence lifetimes of approximately 5.0 and 2.4 ns.
One possible explanation for this behavior is that the lifetimes
reflect contributions from both bound and free DNA (26). In
this interpretation, the shorter lifetime value would represent
the protein bound DNA, and the ;5.0-ns lifetime, the free
DNA. Using this value for the bound DNA, the FRET efficiency
increases from 0.09 to ;0.4, corresponding to a distance change
of 1.9 nm and indicating greater DNA bending (;90 –120°). The
;5.0-ns lifetime value for the free DNA, however, is much
longer than any observed for fluorescein in the single exponential fits of the data, making this explanation unsatisfactory. In
addition, even in the most extreme cases, the discrepancy between the observed data and the single-exponential fits was
fairly small, and the double-exponential fits improved chisquared by at most ;40% over the single exponential fits.
Therefore, in the absence of an adequate explanation for the
weakly multiexponential behavior of some of the decays, we use
the single-exponential decay values to calculate FRET efficiency in all cases.

Sample

Preexponential

Lifetime
ns

E

nm

Pt/Rh/Fl-ds 1 10 eq
HMGdomB
Pt/Rh/Fl-ds 1 20 eq
HMGdomB

3200 6 500
1300 6 600
3700 6 500
1700 6 600

2.4 (2)
4.9 (7)
2.3 (2)
4.6 (5)

0.41 (3)

4.8 (1)

0.44 (4)

4.7 (1)

Efficiency

Distance

Modeling the Bending of the HMG1 Domain B–Cisplatinmodified DNA Complex—The distances determined from the
FRET lifetime experiments were used to estimate a bend angle
for the protein-DNA complex. Figs. 2–5 describe the geometric
model used along with the distances determined from the
single-exponential fits to compute a bend angle for the HMG1
domain B complex with cisplatin-modified DNA. In the first
case examined, geometric parameters for normal B-form DNA
were used along with the distance determined for the unmodified FRET probe. The bending of the cylinder, which created a
5.5-nm separation between the fluorophores, occurred in the
range of 90 –100°. The geometric model was then altered to
examine the effects of DNA unwinding on the estimated bend
angle. A smaller bend of ;70 – 85° obtained when the helical
twist and bend angle range from the x-ray crystal structure
were employed is judged to be less reliable because of duplexduplex packing interactions in the solid state that render these
values less relevant to the solution structure (6). Using the
average helical twist and bend angle range determined for the
NMR solution structures of duplex DNA containing a 1,2-intrastrand d(GpG) cisplatin adduct (7, 36), the 5.5-nm distance
occurred when the DNA was bent by ;80 –95°. The ;60 – 80°
bend and underwinding of the platinated DNA duplex push the
limits of the geometric model used to estimate a bend angle
from the FRET data. In particular, when compared with models where the helical twist and bend angles from B-form DNA
were used, the number of allowed fluorescein and rhodamine
angles were significantly fewer. Moreover, none of the angle
pairs, which yielded a 6.6-nm distance, was in the preferred
position where rhodamine bends toward the DNA. Hence, it is
important to examine these estimated bend angles and see how
they compare with ones determined by other techniques.
The ;80 –95° range estimated using helical twists and bend
angles from the NMR studies of the 1,2-intrastrand d(GpG)
cisplatin adduct seems reasonable, based on the results of
NMR solution studies of DNA complexes with other HMGdomain proteins (38, 39). In the SRY NMR structure, the DNA
is bent by ;70 – 80° (39), and for LEF-1, the DNA is bent by
;117° (38). The bend angle range estimated with our geometric
model falls within the range determined in these NMR studies.
The DNA bending caused by the formation of complexes with
HMG-domain proteins has also been investigated by gel mobility shift assays (12) and x-ray crystallography.3 The bend angle
determined in gel shift studies for the HMG1 domain B complex with a cisplatin-modified DNA probe was ;65–74° (12).
X-ray crystallography shows the bend angle for a cisplatinmodified DNA probe bound to HMG1 domain A to be ;61°.3
Both of these values are smaller than what was estimated from
our geometric models.
The discrepancy between the present bend angle value and
that for other complexes of HMG-domain proteins with plati3
U.-M. Ohndorf, M. A. Rould, Q. He, C. O. Pabo, and S. J. Lippard,
personal communication.
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FIG. 10. Stopped-flow kinetic experiments with HMG1 domain
B. Panel A displays individual shots. Curve 1 is the unmodified duplex
probe with 500 nM HMG1 domain B. Curves 2 and 3 show the cisplatinmodified duplex probe with 188 and 375 nM HMG1 domain B, respectively. Panel B is a plot of the concentration dependent data fitted to
Equation 6, from which were determined kon and koff values of 1.1 6
0.1 3 109 M21 s21 and 30 6 4 s21, respectively.

nated DNA is ascribed in part to differences in experimental
methods. For example, crystal packing forces can affect the
bend angle in an x-ray crystal structure compared with the
FRET studies, where the complex is free in solution. Another
possible contribution to the larger bend angle, estimated here,
could be the different DNA sequence employed. Recent work
indicates that the sequence context surrounding the 1,2-intrastrand d(GpG) cisplatin adduct modulates the binding affinity
of HMG-domain proteins (37) and may influence the ability of
the DNA to bend when an HMG-domain protein binds (6, 37).
In the FRET study, the platinated sequence was TG*G*T,
whereas the sequence in the gel shift assay study was AG*G*C
and in the x-ray study, TG*G*A, where G* denotes the modified
nucleotide. The presence of an additional surrounding A/T base
pair may increase the bendability of the DNA used in the FRET
experiment compared with the gel shift study owing to the
fewer number of hydrogen bonds (37). From these considerations, we conclude that the 80 –95°-bend angle range estimated from the geometric model for these FRET studies is
reasonable.
Rate of HMG1 Domain B Binding to Cisplatin-modified
DNA: Stopped-flow Kinetic Experiments—Stopped-flow kinetic
experiments were performed with both the unmodified and
cisplatin-modified DNA probes containing fluorescent labels.
Fig. 10 portrays results from some of these experiments. In
panel A are presented data from some of the individual shots.
Curve 1 shows the unmodified probe with 500 nM HMG1 domain B. No fluorescence change is observed for this sample.
Curves 2 and 3 exhibit the cisplatin-modified probe in the
presence of 188 and 375 nM HMG1 domain B, respectively.
Here, a decrease in the fluorescein fluorescence is observed
over time that is ascribed to protein binding and concomitant
bending of the DNA. Although the protein concentration is
always in excess, in order to maintain pseudo-first order conditions, the two different concentrations of protein shown in
panel A clearly demonstrate that the rate decrease depends on
protein concentration.
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A concentration-dependent study of the observed rate constants was carried out for the cisplatin-modified probe binding
to HMG1 domain B in order to determine the rate constants for
binding and the dissociation of the complex. The results from
these experiments are illustrated in panel B of Fig. 10. A fit of
the data to Equation 5 gives a second-order rate constant for
binding, kon, of 1.1 6 0.1 3 109 M21 s21 and a first-order rate
constant for the dissociation of the protein-DNA complex, koff,
30 6 4 s21 (t1/2 5 0.023 s). The dissociation constant, Kd,
determined from these rate constants using Equation 6 is 27 6
4 nM, which is in agreement with the value determined in the
fluorescence titration experiments.
The results of these experiments provide the first information about the kinetics of HMG-domain proteins binding to
cisplatin-modified DNA. Very little kinetic information is available for HMG-domain protein binding to DNA in general. Data
that are available were obtained through competition kinetic
gel shift experiments, and not by direct measurement of the
binding event, as accomplished in the present FRET study (40).
The kinetics of binding of an HMG-domain protein to cisplatinmodified DNA is potentially important for understanding its
possible role in sensitizing cells to the drug. Recent experiments examined the interactions of RPA, a protein involved in
DNA damage recognition in the nucleotide excision repair
pathway, and HMG1 to cisplatin-modified DNA (41). The results of these experiments revealed that, when both proteins
were present, HMG1 selectively bound the platinated DNA
(41). One possible explanation for this result is that HMG1
binding to cisplatin-modified DNA occurs at a rate faster than
that of RPA binding and that kinetics controls the competition
(41). The kon value for HMG1 determined here, which is near
the diffusion limit, is consistent with such an explanation.
In conclusion, the present study illustrates the utility of the
FRET technique for investigating the structure and dynamics
of proteins binding to platinated DNA. The method offers the
potential for measuring distances and binding rates in solution
and has an advantage over x-ray crystallographic and gel mobility shift approaches, which do not permit solution studies to
be carried out over a wide range of conditions, such as ionic
strength or pH. FRET experiments can also be performed using
low concentrations of material, an advantage over NMR spectroscopy. Finally, it is relatively easy to alter the nature of the
fluorescent label and to examine FRET distance changes with
different oligonucleotide sequences. By varying the length and
studying a series of oligonucleotide probes, more elaborate
models may be constructed to examine changes in the helical
parameters of the DNA (20, 42).
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